They also examine the lessons learned from a semester of teaching and activism during a tumultuous election season, the national spotlight on social justice, and the COVID pandemic. Finally, they preview the three "rock stars of civic engagement" who will keynote the January 6, Symposium.
A captioned version of this episode is available through this YouTube playlist. Download a transcript of this episode in Adobe PDF format. Request login link. Need an account? Sign Up. See More Offers. Zip Code. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Credit Card. I Agree to the Subscription Terms of Use. This service will be automatically renewed and your credit card billed once it nears expiration.
Your purchase was successful, and you are now logged in. Edit Close. Toggle navigation Menu. Don't have an account? Sign Up Today. He is also a professor of medicine at Harvard Medical School. His research team is also testing the feasibility of adding a FLT3 inhibitor to chemotherapy in patients with newly diagnosed AML and of using a pediatric-like regimen to treat adults with acute lymphoblastic leukemia.
Lung Pasi A. He and his colleagues demonstrated that loss of response to gefitinib Iressa was driven by MET amplification, paving the way for further study of resistance mechanisms to earlier and next-generation inhibitors. Lymphoma Steven T. Rosen was previously director of the Robert H. Rosen is a pioneer in the development monoclonal antibodies and recombinant toxins that can specifically target cancer cells.
He led pivotal research into apoptosis inducers, proteasome inhibitors, and metabolism inhibitors to promote cancer cell death. His research also led to the discovery that RNA-based analogs and cell signaling regulators that can interfere with cancer growth processes. Rosen has been a leader in the discovery of how interferons and cytokines that can trigger an immune response against cancer cells and how angiogenesis inhibitors to prevent cancer from growing new blood vessels.
He has been at the forefront of research into hormone therapies and transcriptional regulators and antisense compounds to activate or silence certain genes in cancer and normal cells.
Melanoma Michael B. Atkins has led several major multi-investigator clinical and translational research efforts. His research in melanoma and kidney cancer has uncovered critical biology of these diseases and led to FDA approval of more than 20 new treatments. Atkins established and led the cutaneous and biologic therapy programs at Beth Israel Deaconess Cancer Center and codeveloped a new staging system for melanoma.
He has published more than scientific and review articles, coedited 5 books, and given more than lectures worldwide. He served as president of the Society for Immunotherapy of Cancer from to
0コメント